- Global Pharma News & Resources

Fertility Partnership of St. Louis Expands Reproductive Services with the Introduction of INVOcell

Fertility Partnership of St. Louis Expands Reproductive Services with the Introduction of INVOcell

PR Newswire

MEDFORD, Mass., Nov. 27, 2018

MEDFORD, Mass., Nov. 27, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcellâ„¢, today announced that the Fertility Partnership of St. Louis, one of the region's leading centers, has added INVOcell to the procedures it utilizes to help its patients achieve pregnancies where traditional reproductive services have succeeded.

Dr. Elan Simckes, founder of the Fertility Partnership, said, "We are pleased to add INVOcell to our palette of reproductive services. INVOcell fits right in with our mission of helping our patients achieve the pregnancies that they passionately desire utilizing a streamlined process that can be done in a very cost-effective manner. We look forward to working with the INVO Bioscience team for many years to come in helping us honor the Fertility Partnership pledge to our patients."

INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman's body, in vivo. The INVO Solution allows women to incubate their own gametes, providing a psychological benefit while reducing the risk of wrong embryo transfer. Utilizing a mild stimulation protocol, it decreases the number of oocytes required, which may reduce the risk of severe ovarian hyperstimulation (OHSS), reduce the risk of multiple births, and/or reduce the need for embryo cryopreservation and storage. As a lower cost option to traditional IVF, INVOcell expands access to patients who otherwise cannot afford the traditional method or would prefer for a more natural, cultural, or religious appropriate choice.

About St. Louis Clinic Fertility Partnership
Fertility Partnership is St. Louis and the Region's leading provider of in vitro fertilization and fertility services. Founded and directed by Dr. Elan Simckes, Fertility Partnership is independent of corporate medicine. St. Louis Fertility Clinic Fertility Partnership is proud to offer one of the most affordable in vitro fertilization services throughout not only St. Louis but the region. Our IVF treatments begin with an initial consultation. Following an initial consultation, an initial health workup begins which includes a physical, pelvic exam, blood tests, and ultrasounds. Once we've completed the health workup, we will work with you to develop the most effective and caring treatment plan. Fertility Partnership is now proud to report a live birth rate of 62%. For more information, please visit

About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit

Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
Kathleen Karloff, CEO
INVO Bioscience, Inc.
978-878-9505 ext. 504


View original content to download multimedia:

SOURCE INVO Bioscience, Inc.

Editor Details

Last Updated: 27-Nov-2018